Maximal Grip Strength
A proven, trusted indicator of overall muscle strength and a key criterion for sarcopenia and frailty.
Advance your research with a validated, patient-centric system for monitoring muscle health and vitality. Eforto® provides objective, high-frequency data to enhance trial efficiency, sensitivity, and the quality of your outcomes.
Clinical trials in geriatrics, neurology, and chronic disease management face a significant challenge: the lack of sensitive, objective, and reliable outcome measures to track disease progression and therapeutic response.
Traditional assessments are often infrequent and burdensome for participants and may miss subtle but clinically meaningful changes.
There is a clear need for validated digital health technologies that allow for objective, remote monitoring of function, providing richer data between clinic visits and capturing real-world patient status
Eforto® is a complete system designed for the rigorous demands of clinical research. Our patented pneumatic vigorimeter, guided mobile app, and secure data platform empower you to capture validated biomarkers of neuromuscular function and vitality capacity with exceptional ease and precision.
Move beyond subjective scales. Eforto® measures objective, WHO-aligned biomarkers for vitality capacity, including:
A proven, trusted indicator of overall muscle strength and a key criterion for sarcopenia and frailty.
A more sensitive biomarker than grip strength alone, shown to be more responsive to interventions and strongly correlates with inflammation and functional decline.
A novel, clinically validated measure that combines objective endurance with subjective fatigue to detect pre-frailty with high accuracy.
Our team is continuously working with research partners to validate and add new, nuanced biomarkers of muscle function. We can work with you to incorporate experimental and advanced metrics into your protocol, including:
To assess muscle power and explosive strength.
To analyze muscle control and relaxation properties.
To compare strength between limbs, critical for neurological and orthopedic studies.
To evaluate the coordination of both hands.
To measure submaximal control and motor stability.
To quantify tremors during exertion using integrated sensors.
Reduce participant burden and increase data density. Eforto® is 5-minute, self-guided test can be performed by participants at home, allowing for daily or weekly data collection that is impossible with traditional clinic-based tests. This provides a more granular view of disease progression or treatment effects.
Add your content here.
High-frequency, objective data can increase the statistical power of your studies, potentially allowing for smaller sample sizes or shorter trial durations. By capturing sensitive changes in muscle fatigability, you may detect a therapeutic signal earlier than with traditional endpoints.
Add your content here.
The Eforto® system is designed for ease of use, even for frail individuals. The interactive app guides participants through the validated protocol, and the ability to see their progress can enhance motivation and long-term adherence to the study protocol.
Add your content here.
We understand that every study is unique. The Eforto® platform is a configurable solution designed for flexibility, allowing you to build custom protocols that precisely match your research objectives. Go beyond standard metrics and integrate bespoke electronic Patient-Reported Outcomes (ePROs) and an expanding list of advanced biomarkers.
Eforto® was developed in collaboration with leading academic partners and validated in multicenter clinical trials. Our platform is built to meet the needs of modern research.
Eforto® is already being used by leading research institutions and is a key component of international studies, including collaborations with the World Health Organization (WHO).
Whether your focus is on frailty, sarcopenia, neuromuscular disease, post-surgical recovery, or the impact of nutritional and pharmacological interventions, Eforto® provides the validated, patient-centric endpoints you need.